Evidence map›Paper›PMID 35596913›Full record

SynthesisQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2022

Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.

Tiffany Li, Susanna B Park, Eva Battaglini, Madeleine T King, Matthew C Kiernan, David Goldstein, Claudia Rutherford

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Assessment tools for peripheral neuropathy in multiple myeloma.The Korean journal of internal medicine · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Self-reported peripheral neuropathic symptoms in long-term adolescent and young adult (AYA) cancer survivors: results of the SURVAYA study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Incidence and associated factors of falls in patients with chemotherapy-induced peripheral neuropathy: a scoping review and evidence mapping.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Compression therapy for taxane-induced peripheral neuropathy: promising results undermined by methodological gaps.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tiffany LiFaculty of Medicine and Health, School of Medical Sciences, Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia. tiffany.li@sydney.edu.au.ORCID http://orcid.org/0000-0003-1138-1489
Susanna B ParkFaculty of Medicine and Health, School of Medical Sciences, Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.
Eva BattagliniPrince of Wales Clinical School, University of New South Wales, Kensington, Australia.
Madeleine T KingFaculty of Science, School of Psychology, Sydney Quality of Life Office, The University of Sydney, Sydney, Australia.
Matthew C KiernanFaculty of Medicine and Health, School of Medical Sciences, Brain and Mind Centre, The University of Sydney, Camperdown, Sydney, NSW, 2050, Australia.
David GoldsteinPrince of Wales Clinical School, University of New South Wales, Kensington, Australia.
Claudia RutherfordFaculty of Science, School of Psychology, Sydney Quality of Life Office, The University of Sydney, Sydney, Australia.

Funding

Cancer Institute NSW 14/TPG/1-05National Health and Medical Research Council Career Development Fellowship #1148595National Health and Medical Research Council Partnership Project #1153439National Health and Medical Research Council Practitioner Fellowship #1156093National Health and Medical Research Council Program Grant #1132524National Health and Medical Research Council Project Grant #1080521
6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity of cancer treatment, with potential to significantly impact cancer survivors' long-term quality of life. Patient reported outcome measures (PROMs) are increasingly utilised to evaluate CIPN. However, guidance remains lacking on how to identify fit for purpose PROMs with considerations necessarily differing when used in various research and in-clinic contexts. This study aimed to evaluate evidence about CIPN PROMs measurement properties and propose considerations to optimize CIPN PROM selection for each purpose.

methodsA systematic review was conducted to identify literature assessing measurement properties of CIPN PROMs. These were evaluated against Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) criteria and International Society for Quality of Life minimum standards. Risk of Bias (RoB) was assessed using the COSMIN RoB checklist.

resultsThirty-nine papers evaluating measurement properties of 13 PROMs were included. The European Organization for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy Questionnaire (QLQ-CIPN20) and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) were the most commonly investigated PROMs and had the most measurement properties meeting established criteria.

conclusionThe use of the QLQ-CIPN20 and FACT/GOG-Ntx to assess CIPN in research settings has the most supporting evidence. However other considerations including study aims, endpoints and target population also factor into PROM selection and need to be considered more often when determining the most suitable outcome measure. Evidence of CIPN PROMs use in clinical practice is limited and their adoption to individual-patient level management requires more evaluation.

Indexed as

Antineoplastic AgentsPeripheral Nervous System DiseasesFemaleHumansPatient Reported Outcome MeasuresPsychometricsQuality of LifeSurveys and QuestionnairesAntineoplastic AgentsCancer survivorsChemotherapy-induced peripheral neuropathyMeasurement propertiesPatient reported outcome measuresPsychometric evaluationSystematic review

Identifiers

PMID35596913
PMCPMC9546984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.